This series on “ALK and ROS-1 NSCLC Patients Treatment Approach Based on Genomic Profile by Liquid Biopsy” is edited by Dr. Jesús Corral, from Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain; Dr. Ernest Nadal, from Department of Medical Oncology, Catalan Institute of Oncology, Barcelona, Spain; Dr. Laura Mezquita, from Thoracic Unit. Hospital Clinic, Barcelona, Spain.
ALK and ROS-1 tyrosine kinase inhibitors (TKIs) have become the new standard of care in the first-line treatment of advanced ALK and ROS-1 positive NSCLC patients. As there are several TKIs, upon progression, the optimal sequential ALK and ROS-1 TKI strategy at progression is relevant, and this may have an impact on patients' outcome. Mechanisms of acquired resistance knowledge will be also relevant to develop new personalized treatment strategies to overcome in the near future.
Mechanisms of resistance after crizotinib or second-generation ALK therapy in advanced non-small cell lung cancer
Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib
Central nervous system progression and liquid biopsy in patients with oncogene addicted non-small cell lung cancer treated with ALK/ROS1 inhibitors
The series “ALK and ROS-1 NSCLC Patients Treatment Approach Based on Genomic Profile by Liquid Biopsy” was commissioned by the editorial office, Precision Cancer Medicine without any sponsorship or funding. Jesús Corral, Laura Mezquita, and Ernest Nadal served as the unpaid Guest Editors for the series.